p38 MAPK-dependent phosphorylation of transcription factor SOX2 promotes an adaptive response to BRAF inhibitors in melanoma cells
Open Access
- 7 August 2022
- journal article
- research article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 298 (9) , 102353
Abstract
No abstract availableKeywords
Funding Information
- Università degli Studi di Padova (21168, BIRD189887/18)
- Associazione Italiana per la Ricerca sul Cancro (IG-23091, IG-23719)
This publication has 48 references indexed in Scilit:
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic MelanomaJournal of Clinical Oncology, 2013
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Hedgehog‐EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour‐initiating pancreatic cancer cellsEMBO Molecular Medicine, 2012
- Sox2 expression in breast tumours and activation in breast cancer stem cellsOncogene, 2011
- Phosphorylation of Sox2 Cooperates in Reprogramming to Pluripotent Stem CellsStem Cells, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- Phosphorylation Dynamics during Early Differentiation of Human Embryonic Stem CellsCell Stem Cell, 2009
- Acetylation of Sox2 Induces its Nuclear Export in Embryonic Stem CellsStem Cells, 2009
- Inhibition of DNA binding of Sox2 by the SUMO conjugationBiochemical and Biophysical Research Communications, 2006
- The search for physiological substrates of MAP and SAP kinases in mammalian cellsTrends in Cell Biology, 1997